Full Name
Josh Schimmer
Job Title
Fundamental Research Analyst
Company Name
Evercore ISI
Bio
Josh Schimmer is a senior managing director on Evercore ISI’s Biotech Team, focusing on small-, mid- and select large-cap biotechnology companies. In 2021, he was again ranked No. 1 in Institutional Investor’s All America Research Team for SMID biotech, a position he has maintained since 2018. He was runner-up in 2015 and 2016.
Dr. Schimmer, who has more than 15 years of biotechnology research experience, previously worked at Piper Jaffray, Lazard Capital Markets, Leerink Partners, and Cowen & Co. In addition, he spent two years on the buy-side at Davidson Kempner.
Dr. Schimmer received his M.D. and subspeciality training in internal medicine and rheumatology from the University of Toronto and earned an MBA from Harvard Business School.
Dr. Schimmer, who has more than 15 years of biotechnology research experience, previously worked at Piper Jaffray, Lazard Capital Markets, Leerink Partners, and Cowen & Co. In addition, he spent two years on the buy-side at Davidson Kempner.
Dr. Schimmer received his M.D. and subspeciality training in internal medicine and rheumatology from the University of Toronto and earned an MBA from Harvard Business School.
Company Description
Evercore was in 1995, on the premise that clients would be best served by an investment banking firm free of the conflicts of interest inherent to large, multi-product financial institutions. We believed our model would attract the most talented senior finance professionals to our firm. We believed that by maintaining the highest standards of excellence we could create a firm unlike any other in terms of capabilities to advise on highly complex strategic transactions, dedication to our client and our experience and professionalism.
Today, we serve a prominent and diverse set of clients and investors, including leading multinational corporations, large institutional investors and financial sponsors, and high net worth individuals.
Today, we serve a prominent and diverse set of clients and investors, including leading multinational corporations, large institutional investors and financial sponsors, and high net worth individuals.
Company Website
